Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CANDIDA LUSITANIAE - AN IMPORTANT EMERGING CAUSE OF CANDIDEMIA
Autore:
NGUYEN MH; MORRIS AJ; DOBSON ME; SNYDMAN DR; PEACOCK JE; RINALDI MG; YU VL;
Indirizzi:
UNIV PITTSBURGH,SCH MED,DIV INFECT DIS,501 KAUFMAN BLDG PITTSBURGH PA15213 UNIV PITTSBURGH,SCH MED,DIV INFECT DIS PITTSBURGH PA 15213 DUKE UNIV,MED CTR DURHAM NC 00000 TUFTS UNIV NEW ENGLAND MED CTR BOSTON MA 02111 BOWMAN GRAY SCH MED WINSTON SALEM NC 00000 UNIV TEXAS,HLTH SCI CTR SAN ANTONIO TX 00000
Titolo Testata:
Infectious diseases in clinical practice
fascicolo: 4, volume: 5, anno: 1996,
pagine: 273 - 278
SICI:
1056-9103(1996)5:4<273:CL-AIE>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMPHOTERICIN-B; OPPORTUNISTIC PATHOGEN; FUNGEMIA; INFECTION; RESISTANCE; EPIDEMIOLOGY; FLUCONAZOLE; MORTALITY; FREQUENCY; HOST;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
M.H. Nguyen et al., "CANDIDA LUSITANIAE - AN IMPORTANT EMERGING CAUSE OF CANDIDEMIA", Infectious diseases in clinical practice, 5(4), 1996, pp. 273-278

Abstract

Candida lusitaniae is a rare cause of candidemia, with only 15 cases previously reported in the medical literature. We describe five additional cases of C. lusitaniae fungemia and one case of culture- and histopathology-proven C. lusitaniae skin infection. We also review the other 15 cases reported in the literature. Microbiologicpersistence appears to be the hallmark of C. lusitaniae infection, with 33% of our patients and 67% of those previously reported demonstrating persistent infection with amphotericin B (AmB) therapy. Despite the common belief that C. lusitaniae is resistant to AmB, we found all of our isolates were susceptible in vitro to AmB except for one isolate from a patient who had received prior AmB therapy. Moreover, four of our six patients were successfully treated with AmB. We describe two cases of C. lusitaniae breakthrough fungemia occurring during fluconazole therapy, AmB appears to be the drug of choice for patients with C. lusitaniae fungemia, although we documented one case of successful therapy with fluconazole. All patients should be closely monitored during therapy for the possible emergence of antifungal resistance.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 13:24:56